Your browser doesn't support javascript.
loading
Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma.
Nader Marta, Guilherme; Isaacsson Velho, Pedro; Bonadio, Renata R C; Nardo, Mirella; Faraj, Sheila F; de Azevedo Souza, Manoel Carlos L; Muniz, David Q B; Bastos, Diogo Assed; Dzik, Carlos.
Afiliação
  • Nader Marta G; Instituto do Cancer do Estado de Sao Paulo, Av. Dr. Arnaldo, 251, Sao Paulo, SP, 01246-000, Brazil. guilherme.marta@usp.br.
  • Isaacsson Velho P; Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
  • Bonadio RRC; Hospital Moinhos de Vento, Porto Alegre, Brazil.
  • Nardo M; Instituto do Cancer do Estado de Sao Paulo, Av. Dr. Arnaldo, 251, Sao Paulo, SP, 01246-000, Brazil.
  • Faraj SF; Instituto do Cancer do Estado de Sao Paulo, Av. Dr. Arnaldo, 251, Sao Paulo, SP, 01246-000, Brazil.
  • de Azevedo Souza MCL; Instituto do Cancer do Estado de Sao Paulo, Av. Dr. Arnaldo, 251, Sao Paulo, SP, 01246-000, Brazil.
  • Muniz DQB; Instituto do Cancer do Estado de Sao Paulo, Av. Dr. Arnaldo, 251, Sao Paulo, SP, 01246-000, Brazil.
  • Bastos DA; Instituto do Cancer do Estado de Sao Paulo, Av. Dr. Arnaldo, 251, Sao Paulo, SP, 01246-000, Brazil.
  • Dzik C; Instituto do Cancer do Estado de Sao Paulo, Av. Dr. Arnaldo, 251, Sao Paulo, SP, 01246-000, Brazil.
Pathol Oncol Res ; 26(4): 2489-2497, 2020 Oct.
Article em En | MEDLINE | ID: mdl-32583330
Metastatic renal cell carcinoma (mRCC) encompasses a heterogeneous group of neoplasms with distinct clinical behavior and prognoses. As a result of the increasing number of therapeutic options in the metastatic setting, it is crucial to improve prognostic stratification ability. We aimed to evaluate the prognostic value of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and combination platelet count and neutrophil lymphocyte ratio (COP-NLR) in patients with mRCC. We evaluated a cohort of mRCC patients treated with first-line pazopanib or sunitinib. Levels of NLR, PLR and COP-NLR were measured prior to systemic treatment and evaluated as prognostic predictors. Primary endpoint was overall survival (OS). Data from 276 patients were included, of which 54.7% received first-line pazopanib and 45.3%, sunitinib. Memorial Sloan-Kettering Cancer Center risk classification was intermediate and poor in 50% and 42.6% of patients, respectively. High NLR (> 3.5) was associated with inferior OS (median 9.6 vs 17.8 months, P < 0.001). A high PLR (> 200) was associated with inferior OS (median 10.3 vs 17 months, P = 0.002). The median OS in the COP-NLR 1, 2 and 3 groups were 19.0 months (95% CI 15.3-26.0), 13.1 months (95% CI 9.8-17.0) and 7.4 months (95% CI 3.6-11.9), respectively (P < 0.001). In the multivariate analysis, high NLR and high COP-NLR were associated with inferior OS. Both high NLR and high COP-NLR were associated with poorer OS in our cohort of patients with mRCC treated with first-line pazopanib or sunitinib.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Biomarcadores Tumorais / Neoplasias Renais / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged Idioma: En Revista: Pathol Oncol Res Assunto da revista: NEOPLASIAS / PATOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Biomarcadores Tumorais / Neoplasias Renais / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged Idioma: En Revista: Pathol Oncol Res Assunto da revista: NEOPLASIAS / PATOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça